MedTrace Logo

CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma

NCT03146234 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2019-08-28

No results posted yet for this study

Summary

This study is designed to determine the safety and efficacy of CAR-GPC3 T cells in patients with relapsed or refractory hepatocellular carcinoma. Single or multiple doses of GPC3-targeted CAR T cells will be given to subjects with unmet medical needs for which there are no effective therapies known at this time.

Conditions

Interventions

GENETIC

CAR-GPC3 T cells

Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled. Classical "3+3" dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study.

Sponsors & Collaborators

  • CARsgen Therapeutics Co., Ltd.

    collaborator INDUSTRY

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Bo Zhai, MD · RenJi Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-17
Primary Completion
2018-10-18
Completion
2018-10-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03146234 on ClinicalTrials.gov